Novartis has revealed promising topline results from two Phase III clinical trials assessing remibrutinib for adults with relapsing multiple sclerosis (RMS). Both studies successfully met their primary endpoints, showing significant reductions in annualized relapse rates when compared to teriflunomide.
Trial Overview
The REMODEL-1 and REMODEL-2 trials, which were designed identically, also showcased the superiority of remibrutinib across all key secondary endpoints. Notably, these included significant decreases in MRI-detected brain lesions.
Disability Progression Analysis
A preplanned combined analysis indicated a clinically meaningful delay in disability progression. This analysis highlighted a positive trend in three-month confirmed disability progression and a nominally significant finding in six-month confirmed disability progression.
Safety Profile
Remibrutinib maintained a favorable safety profile, consistent with Novartis’s extensive development program, which has involved over 4,500 clinical trial participants across various indications. Notably, there were no liver safety concerns, including any cases that met Hy’s Law criteria.
Future Plans
Novartis intends to present comprehensive results from the REMODEL-1 and REMODEL-2 trials as late-breaking data at the upcoming MSToronto2026 conference. The company also plans to pursue global regulatory approval for remibrutinib in the treatment of relapsing multiple sclerosis.
Mechanism of Action
Remibrutinib functions as a highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor. By blocking the BTK pathway, it reduces the activation of B cells and innate immune cells, which are crucial in immune regulation and neuroinflammation.
Broader Applications
In addition to its use for relapsing multiple sclerosis, remibrutinib is currently being studied in the REMASTER Phase III program for secondary progressive multiple sclerosis and other immune-mediated diseases. It is already approved in the United States and European Union under the name Rhapsido for adults suffering from chronic spontaneous urticaria.
Study Participation
The REMODEL trials involved approximately 2,000 global participants who exhibited recent disease activity. Participants were randomized to receive either remibrutinib at a dosage of 100 mg or teriflunomide.
These studies included a double-blind core phase lasting up to 30 months, followed by an open-label extension period that could extend up to five years.
Statement from Novartis
“Despite advances in treatment, there remains an unmet need for oral therapies that effectively prevent relapses, slow disability progression, and maintain a favorable safety profile,” stated Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis. “The positive outcomes from the REMODEL trials highlight remibrutinib’s potential as a high-efficacy oral therapy for individuals living with RMS, showcasing a differentiated benefit-risk profile. We are committed to advancing care in multiple sclerosis and these findings strengthen our ambition to drive innovation in this area.”
In conclusion, Novartis’s successful results from the REMODEL trials reinforce the potential impact of remibrutinib in the treatment of relapsing multiple sclerosis. As the company moves towards regulatory approval and further research, this development could significantly improve the lives of those affected by this condition.
- Key takeaways:
- Both Phase III trials of remibrutinib met primary endpoints.
- Significant reduction in annualized relapse rates compared to teriflunomide.
- Favorable safety profile with no liver safety signals.
- Remibrutinib also being studied for secondary progressive multiple sclerosis.
- Results will be presented at MSToronto2026.
Read more → pulse2.com